Novo Nordisk stock jumps after drugmaker wins US approval for weight-loss pill

Key Points

  • Novo Nordisk's Breakthrough: The U.S. FDA approved Novo Nordisk's oral weight-loss pill, a 25 mg dose of semaglutide, branded as Wegovy, marking a significant step in the race for oral obesity treatments.**
  • Competitive Edge: This approval positions Novo Nordisk ahead of rival Eli Lilly, helping to recover from a challenging year of declining shares and sales of injectable Wegovy.**
  • Clinical Results: A 64-week study showed that participants on the oral semaglutide lost an average of 16.6% of their body weight, compared to just 2.7% for those on placebo.**
  • Market Impact: Shares of Novo Nordisk surged over 8% following the announcement, reflecting strong investor confidence in the drug's potential.**
  • Broad Application: The pill is approved for chronic weight management in adults with obesity or overweight and related health conditions, targeting a vast patient pool amid rising healthcare costs.**

Summary

The U.S. Food and Drug Administration has approved Novo Nordisk's oral weight-loss pill, a 25 mg dose of semaglutide sold as Wegovy, marking a pivotal moment for the Danish drugmaker in the competitive obesity treatment market. This approval, announced on December 22, gives Novo an edge over rival Eli Lilly, especially after a tough year of declining shares and slowing sales of its injectable Wegovy due to competition and compounded versions. A late-stage study demonstrated impressive results, with participants losing an average of 16.6% of their body weight over 64 weeks compared to 2.7% on placebo. Approved for chronic weight management in adults with obesity or overweight and related conditions, the pill targets a massive potential market, projected to reach $150 billion annually by the next decade. Novo’s shares jumped over 8% in early trading, signaling strong market optimism. This development could open access to millions of patients globally, addressing spiraling healthcare costs linked to obesity while bolstering Novo Nordisk’s position in the industry.

yahoo
December 23, 2025
Stocks
Read article

Related news